This noninferiority trial compares the effects of zoledronic acid administered every 12 weeks vs every 4 weeks over 2 years on prevention of skeletal events in patients with bone metastases due to breast cancer, prostate cancer, or multiple myeloma.
This Swedish cohort study investigates whether treatment with alendronate is associated with reduced risk of hip fracture among older patients using oral glucocorticoids.
This review summarizes advances in risk classification methods, imaging techniques, biomarkers for diagnosis, and treatments for prostate cancer.
This Viewpoint outlines the diagnostic approaches and treatment options to reduce risk of fracture among patients with osteoporosis.
You currently have no searches saved.